KRAS early testing. Consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an italian setting by Barone, C. et al.
KRAS Early Testing: Consensus Initiative and Cost-
Effectiveness Evaluation for Metastatic Colorectal
Patients in an Italian Setting
Carlo Barone1*, Carmine Pinto2, Nicola Normanno3, Lorenzo Capussotti4, Francesco Cognetti5,
Alfredo Falcone6, Lorenzo Mantovani7
1Medical Oncology Unit, Gemelli Hospital, Rome, Italy, 2Medical Oncology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy, 3Cellular Biology and Biotherapies Unit,
Pascale Foundation, Naples, Italy, 4General and Oncological Surgery, Umberto I Hospital, Turin, Italy, 5Medical Oncology Department, Regina Elena Hospital, Rome, Italy,
6Oncology, Transplantations and New Medical Technologies Department, Santa Chiara Hospital, Pisa, Italy, 7Clinical Medicine and Surgery Unit, Federico II University of
Naples, Naples, Italy
Abstract
KRAS testing is relevant for the choice of the most appropriate first-line therapy of metastatic colorectal cancer (CRC).
Strategies for preventing unequal access to the test should be implemented, but their relevance in the practice is related to
economic sustainability. The study adopted the Delphi technique to reach a consensus on several topics. Issues related to
execution of KRAS testing were identified by an expert’s board and proposed to 108 Italian oncologists and pathologists
through two subsequent questionnaires. The emerging proposal was evaluated by decision analyses models employed by
technology assessment agencies in order to assess cost-effectiveness. Alternative therapeutic strategies included most
commonly used chemotherapy regimens alone or in combination with cetuximab or bevacizumab. The survey indicated
that time interval for obtaining KRAS test should not exceed 15 days, 10 days being an optimal interval. To assure the access
to proper treatment, a useful strategy should be to anticipate the test after radical resection in patients at high risk of
relapse. Early KRAS testing in high risk CRC patients generates incremental cost-effectiveness ratios between 6,000 and
13,000 Euro per quality adjusted life year (QALY) gained. In extensive sensitivity analyses ICER’s were always below 15,000
Euro per QALY gained, far within the threshold of 60,000 Euro/QALY gained accepted by regulatory institutions in Italy. In
metastatic CRC a time interval higher than 15 days for result of KRAS testing limits access to therapeutic choices.
Anticipating KRAS testing before the onset of metastatic disease in patients at high risk does not affect the sustainability
and cost-effectiveness profile of cetuximab in first-line mCRC. Early KRAS testing may prevent this inequality in high-risk
patients, whether they develop metastases, and is a cost-effective strategy. Based on these results, present joined
recommendations of Italian societies of Oncology and Pathology should be updated including early KRAS testing.
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Introduction
Since 2008 KRAS mutational status has become the main tissue
biomarker of resistance to anti-EGFR monoclonal antibodies in
metastatic colorectal cancer (CRC). Large phase III and random-
ized phase II studies have demonstrated that mutation of KRAS
gene predicts resistance to treatment with an anti-EGFR antibody
either alone or in combination with chemotherapy [1,2]. The
effect of combination of anti-EGFR antibody and chemotherapy
seems particularly relevant in patients with liver limited initially
not resectable disease [3,4]. Furthermore, in palliative setting the
addition of anti-EGFR monoclonal antibodies to chemotherapy
regimens increases the progression free survival and overall
survival [5]. Only in few studies biased by selection and
methodological issues the predictive role of KRAS has not clearly
emerged; however, also in one of these studies response rate was
significantly higher in wild-type (wt) tumors [6,7].
The most accepted guidelines now consider KRAS mutation
status a central step of decision-making process in the therapy of
metastatic CRC, both in potentially resectable and palliative
treatment settings. Access to the advantage provided by this test,
however, may be limited by some practical difficulties that may
hinder the therapeutic opportunities resulting from anti-EGFR
targeting therapy. Mutational analysis, in fact, needs technical and
expertise resources that may be not everywhere available [8]. Both
complexity of the test and different access to molecular biology
laboratory may cause delays, which often conflict with the urgency
of clinical decision. This means that an unknown, but not
irrelevant, percentage of patients is excluded from a potential
therapeutic advantage with negative consequences either on
symptom control or resection rate and survival.
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The peculiarity of the Italian situation can be clearly seen from
the data collected with the KRAS aKtive system, a network aimed
to facilitate KRAS testing in Italy. In the period from 1 January
2011 to 31 December 2011, this project has involved 407
oncologists and 125 pathologists, and 24 reference laboratories
in 16 of the 21 Italian regions [9]. The times to the diagnosis in
most of involved regions result more than 15 days: with the
exception of the only region of Puglia, all other times are longer
than 10 days and, except Lazio and Tuscany, all are over 15 days
(Figure 1). This value is similar to that found in a retrospective
study including 160 French centers, where the median time
between prescription and result of the K-RAS testing was 19
months [10].
In addition to differences in reaching the needed resources for
KRAS test, economic concerns may have the potential to
constrain the use of anti-EGFR antibodies, despite the large
evidence resulting from clinical trials. Recently, a health technol-
ogy assessment report has evaluated the clinical and economic
profile of cetuximab in first-line metastatic colorectal cancer
(mCRC) in Italy on a specific population (KRAS wt liver limited
disease patients). The economic analysis of cetuximab in the
treatment of metastatic colorectal cancer shows that this therapy,
in combination with FOLFOX and FOLFIRI, is more cost-
effective than the alternatives currently available in first line
(bevacizumab+FOLFOX, FOLFOX, FOLFIRI); therefore cetux-
imab can be considered as a sustainable alternative for the NHS
[11].
Among the possible strategies, aimed to equalize patients
opportunity of access to the potential advantage of anti-EGFR
strategy, the anticipation of KRAS testing might be of value. In the
present study we have analyzed the opinion and the attitude of a
representative group of Italian specialists, mainly oncologists and
pathologists, on the implication of KRAS testing in order to
optimize overall therapeutic approach to patients with metastatic
CRC. The economic supportability of a different strategy of
KRAS testing was assessed by a specifically modeled cost-
effectiveness analysis.
Methods
Delphi Technique
The Delphi technique is a validated consensus-building process
to develop consensus and make group-based decisions in a variety
of fields [12,13]. It was conceived and developed in the mid-1950s
by researchers at the Rand Corporation as a way to predict the
impact of technologies or interventions on complex systems, which
has often been used in the social and health care context [14–16].
The Delphi method (Figure 2) is traditionally based on three
fundamental concepts. The first is anonymity. The participants
never meet each other during the process. Each participant
submits his or her opinion independently, by completing a
specially designed questionnaire. The replies are then disclosed
to all participants, without identifying the particular respondent.
The second concept is controlled feedback. The process consists of
several rounds; during each of them the respondents are asked to
judge all the opinions expressed in the previous rounds, often
presented in the form of statistics. The last concept is statistical
group response. The Delphi method reaches a collective decision
Figure 1. KRAS aKtive program in Italy – Requested time (days) to diagnosis –2011.
doi:10.1371/journal.pone.0085897.g001
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and expresses it in terms of a statistical score. In addition to these
basic characteristics, the Delphi method can be described as
follows:
N It requires individual effort for the expression of an opinion.
N It requires written answers to questionnaires.
N The individual opinions (questionnaire responses) are collected
and assembled by the project coordinator.
N The respondents have enough time to come up with and
evaluate opinions (unlike task force meeting, in which, quite
often, not enough time is allowed to assess other people’s
opinions).
Delphi method was used specifically in the field of oncology and
diagnostic test assessment for epidemiological, inhabitant aware-
ness and behavior, and to set up and define healthcare protocols
and procedures and treatment guidelines [17–27].
For the purpose of this specific project, a small group of
specialists, the board of experts (comprised of six major specialists
selected from Italian universities and public hospitals and one
pharmacoeconomist) examined the scientific literature and devel-
oped a 22-item questionnaire (Q1; see Table 1), including 4
demographic initial questions. The questionnaire was designed for
an expert panel consisting of 108 oncologists, pathologists,
molecular biologists, surgeons, quite all of them persons in charge
of hospital departments, randomly selected from different Italian
regions.
Q1 was written in order to avoid possible bias caused by
inadvertently influencing replies, so the sequence of questions was
ordered within a framework of three mains chapters (Management
of patients with metastatic colorectal cancer; Definition of
operated patient at high risk of relapse; Anticipation of KRAS
testing at the diagnosis of primary tumor). For each question,
space was provided for comments.
The majority of Q1 questions (11 out of 18) allowed a classified
answer on a scale of 0 (total disagreement) to 9 (complete
agreement) while other asked the responders either to rank a set of
provided options in order of relevance following their clinical
opinion, or to fill in open-ended questions.
To better analyze the replies, two categories of answers were
defined for the questions with a 0–9 range:
N Score 0–4: negative answer;
N Score 5–9: positive answer.
After the replies to Q1 were processed, a second questionnaire
(Q2) was developed (Table 2). Q2 was presented to the same
expert panel and replies were collected and processed in the same
way, as done with Q1.
After both rounds, the level of agreement was evaluated based
on the percentage of positive answers to each question. To reach
consensus, a cut-off level of two-thirds (67%) of agreement (for
positive or negative answers) was required for the first (Q1) and the
second round (Q2). These arbitrary but standard consensus levels
were agreed on by all members of the board before beginning the
study.
Cost-effectiveness Analysis
In order to assess the cost-effectiveness of early KRAS testing in
high-risk non metastatic CRC patients, we adapted a model
previously used to assess the cost effectiveness of cetuximab plus
chemotherapy vs chemotherapy alone or chemotherapy plus
bevacizumab, i.e. the only other biologic agent to date approved
in Italy in first line colorectal cancer [11]. The model has been
developed and adapted based on models previously used in
assessments performed by technology assessment agencies, e.g.
NICE [28] and SMC [29].
Alternative therapeutic strategies included chemotherapy regi-
mens (FOLFOX4, FOLFIRI), and biological drugs in combina-
tion with chemotherapy (cetuximab+FOLFOX-4, cetuximab+-
FOLFIRI, bevacizumab+FOLFOX4). The models were adapted
to take into account for early KRAS testing in high-risk patients in
Figure 2. Phases of the Delphi method.
doi:10.1371/journal.pone.0085897.g002
KRAS Early Test in Metastatic Colorectal Patients
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e85897
Table 1. Questionnaire 1.
QUESTION
% all
options
% combined
options (0–4/5–9) Consensus
5. In the institution where you work, the laboratory conducting the KRAS test:
a. is the same pathological anatomy and is based in your own hospital 47.66%
b. is different from the pathological anatomy and is based in your own hospital 15.89%
c. is the same pathological anatomy based in a different seat from your hospital but in the
same local health structure
2.80%
d. is the same pathological anatomy based in a different seat from your hospital and in a
different local health structure
7.48%
e. is different from the pathological anatomy based in a different seat from your hospital but in the
same local health structure
1.87%
f. is different from the pathological anatomy based in a different seat from your hospital and in a
different local health structure
22.43%
g. other (specify) 1.87%
6. In the institution where you work, the time elapsing from the request of KRAS testing
to obtainment of the results is:
a. #7 days 26.92%
b. 8–14 days 43.27%
c. 15–21 days 23.08%
d. 22–28 days 5.77%
e. .28 days 0.96%
7. Do you think that the time required to obtain the response in a patient with metastatic
CRC who is to receive a first line chemotherapy:
a. does not affect treatment choices 39.58%
b. negatively affects treatment choices 19.79%
c. limits the first line use of anti-EGFR monoclonal antibodies 38.54%
d. other (specify) 2.08%
8. The best time to take the test for the detection of KRAS is at the diagnosis of
potentially resectable liver metastases.
NO
0 total disagreement 9.18%
1 4.08%
2 8.16% 33.67%
3 10.20%
4 2.04%
5 6.12%
6 8.16%
7 9.18% 66.33%
8 14.29%
9 complete agreement 28.57%
9. The best time to take the test for KRAS is after radical resection of colorectal cancer in
patients at high risk of relapse in order to have the data at the onset of metastases.
YES
0 total disagreement 4.04%
1 3.03%
2 7.07% 26.26%
3 9.09%
4 3.03%
5 6.06%
6 7.07%
7 7.07% 73.74%
8 15.15%
9 complete agreement 38.38%
10. If you believe that the time for the determination of KRAS mutations is inadequate,
which are the causes that produce this delay you deem most important? (ranking 1 to 6)
Score + Rank
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Table 1. Cont.
QUESTION
% all
options
% combined
options (0–4/5–9) Consensus
a. Technical problems of the laboratory 211 1
b. Secretarial/bureaucratic issues 209 2
c. Availability of the material in the archive 180 4
d. Finding material in the archive 192 3
e. Sample preparation for testing 164 5
f. Sending the sample to be examined 192 3
g. Other (specify) 12 6
11. If the waiting time of KRAS test results are too long, the oncologist may decide the
therapeutic strategy even without considering the possibility of a personalized therapy.
NO
0 total disagreement 12.63%
1 7.37%
2 14.74% 55.79%
3 9.47%
4 11.58%
5 10.53%
6 9.47%
7 11.58% 44.21%
8 5.26%
9 complete agreement 7.37%
12. In patients with CRC and potentially resectable liver metastases susceptible to a
conversion therapy, waiting times for KRAS test results must be adequate to ensure the
oncologist the possible use of an anti-EGFR monoclonal antibody in combination with
chemotherapy.
YES
0 total disagreement 1.04%
1 0.00%
2 0.00% 2.08%
3 1.04%
4 0.00%
5 4.17%
6 1.04%
7 7.29% 97.92%
8 16.67%
9 complete agreement 68.75%
13. The evaluation of KRAS allows an efficient use of resources, ensuring in this way the
selection the most appropriate and targeted treatment.
YES
0 total disagreement 0.00%
1 0.00%
2 0.00% 1.01%
3 0.00%
4 1.01%
5 0.00%
6 1.01%
7 14.14% 98.99%
8 24.24%
9 complete agreement 59.60%
14. The evaluation of KRAS in the primary tumour in patients at high risk is a financially
sustainable strategy allowing the prompt use of the most appropriate therapy when the
patient metastasizes.
YES
0 total disagreement 3.03%
1 4.04%
2 7.07% 25.25%
KRAS Early Test in Metastatic Colorectal Patients
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Table 1. Cont.
QUESTION
% all
options
% combined
options (0–4/5–9) Consensus
3 7.07%
4 4.04%
5 4.04%
6 3.03%
7 14.14% 74.75%
8 20.20%
9 complete agreement 33.33%
15. There is sufficient scientific literature that defines the operated patient at high risk of
relapse.
YES
0 total disagreement 0.00%
1 0.00%
2 1.05% 14.74%
3 6.32%
4 7.37%
5 9.47%
6 15.79%
7 24.21% 85.26%
8 22.11%
9 complete agreement 13.68%
16. In radically operated patients N0 at diagnosis, what are the prognostic factors to be
taken into account? (ranking 1 to 6)
Score + Rank
a. pT4 394 1
b. Grading 306 2
c. Lymph angioinvasion 271 4
d. Mucinous histotype 184 5
e. Intestinal occlusion-perforation 297 3
f. Value of CEA 126 6
g. Other (specify) 21 7
17. In radically operated patients N+ at diagnosis, what are the prognostic factors to be
taken into account? (ranking 1 to 7)
Score + Rank
a. pT4 376 2
b. pN1 358 3
c. pN2 502 1
d. Mucinous histotype 213 6
e. Lymph angioinvasion 280 4
f. Value of CEA 137 7
g. Intestinal occlusion-perforation 265 5
h. Other (specify) 9 8
18. In patients with surgically removed isolated peritoneal carcinomatosis and/or
positive peritoneal washing and/or removed ovarian metastases the determination
for KRAS should always be performed.
YES
0 total disagreement 4.30%
1 0.00%
2 3.23% 13.98%
3 3.23%
4 3.23%
5 2.15%
6 4.30%
7 13.98% 86.02%
8 21.51%
KRAS Early Test in Metastatic Colorectal Patients
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those cases in which a deferred test would impair a well-timed
treatment including cetuximab. The models have been populated
with Italy specific cost data (drugs, tests, hospital admissions,
administration, toxicity management, etc.), incorporating patients’
access schemes (cost/risk sharing agreements and capping) as
described in details in the SMC assessment [29].
Not all patients at high risk would eventually develop metastases
and would therefore be candidate for treatment with cetuximab.
Table 1. Cont.
QUESTION
% all
options
% combined
options (0–4/5–9) Consensus
9 complete agreement 44.09%
19. The determination of KRAS status is a key element in deciding the therapeutic
strategy of patients with metastatic colorectal cancer.
YES
0 total disagreement 0.00%
1 0.00%
2 0.98% 3.92%
3 0.98%
4 1.96%
5 2.94%
6 2.94%
7 11.76% 96.08%
8 21.57%
9 complete agreement 56.86%
20. For the characterization of a colorectal tumour the evaluation of KRAS mutation
status is the only molecular parameter to be considered in clinical practice.
NO
0 total disagreement 8.82%
1 4.90%
2 4.90% 38.24%
3 8.82%
4 10.78%
5 10.78%
6 14.71%
7 13.73% 61.76%
8 10.78%
9 complete agreement 11.76%
21. In clinical practice which molecular parameters do you use routinely for selecting
the first line treatment in patients with metastatic colorectal cancer?
a. KRAS mutations (only exon 12, 13) 68 51.13%
b. KRAS mutations (all mutations) 32 24.06%
c. BRAF mutations 26 19.55%
d. PI3K mutations 2 1.50%
e. State of PTEN 3 2.26%
g. Other (specify) 2 1.50%
22. The material for KRAS testing is either the primary tumour or the metastases. YES
0 total disagreement 1.96%
1 0.00%
2 3.92% 17.65%
3 3.92%
4 7.84%
5 7.84%
6 6.86%
7 16.67% 82.35%
8 13.73%
9 complete agreement 37.25%
Answers are expressed as percentage of all responses. Cut-off level to reach consensus: two-thirds (67%) of agreement of effective answers.
doi:10.1371/journal.pone.0085897.t001
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The cost effectiveness of early KRAS testing mimics the situation
in which part of KRAS test would be performed in vain (i.e. for
those patients who would not eventually develop metastases), and
part would only be anticipated (i.e. for those who would
subsequently develop metastases). Computationally, this is equiv-
alent to adding to the population of patients eventually developing
metastatic disease and being treated, the cost of KRAS tests of the
population of patients that would not develop metastases and for
which the test would have not been necessary. The size of these
two populations depends on the level of risk of developing
metastatic disease. In order to simulate the incremental cost
effectiveness that would be generated by early KRAS testing in
high risk patients and to test the robustness of results, we
conducted several analyses under different assumptions, by setting
Table 2. Questionnaire 2.
QUESTION % all options Consensus
3. In the institution where you work, the time elapsing from
the request of KRAS testing to obtainment of the results is:
a. #7 days 29.79%
b. 8–14 days 44.68%
c. 15–21 days 17.02%
d. 22–28 days 6.38%
e. .28 days 2.13%
4. Do you think that in a patient with metastatic CRC who is to receive a first line chemotherapy a
time interval longer than 15 days for obtaining the response could limit the therapeutic choices?
YES
a. Yes 74.73%
b. No 25.27%
5. If so, what do you think is the maximum waiting time for KRAS test results to proceed with
a therapy? (in days)
Average 10
Median 9
6. Do you think that the best time to take the test for KRAS is at the onset of the metastatic disease? NO
a. Yes 60.22%
b. No 39.78%
6.a. If no, which you think is the best time?
At diagnosis, especially in patients at high risk of relapse (10) 40%
At the surgery, in patients at high risk of recurrence (13) 52%
6.b. Do you think it is all the way useful to anticipate it? YES
a. Yes 72.04%
b. No 27.96%
7. If the waiting time for KRAS test results are too long, should the oncologist decide to go ahead
with alternative therapeutic strategies giving up the opportunity to use a personalized therapy?
a. Yes 51.19%
b. No 48.81%
7.a. Do you think that the possible treatment choice alternative to personalized therapy is
equally effective?
a. Yes 36.14%
b. No 63.86%
8. Is the evaluation of KRAS in the primary tumour in patients at high risk, so to promptly use the most
appropriate therapy when the patient metastasizes, a sustainable strategy?
YES
a. Yes 74.47%
b. No 25.53%
8.a. If no, please state if this is due to:
a. Organizational reasons 32.35%
b. Financial reasons 67.65%
9. In the light of the anti-EGFR filed indications and of the supporting scientific data, do you think
that the KRAS is the only molecular parameter to consider in clinical practice?
NO
a. Yes 43.62%
b. No 56.38%
Answers are expressed as percentage of all responses. Cut-off level to reach consensus: two-thirds (67%) of agreement of effective answers.
doi:10.1371/journal.pone.0085897.t002
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the level of risk of developing metastatic disease at the level of 1
patients out of 2 (i.e. 50% chance), 1/3, 1/4, 1/5 and 1/10, i.e.
including very low risk. The cost of KRAS test is quantified at 160
Euro per test. Costs are expressed in Euro of 2012 and effects are
expressed in quality adjusted life years (QALY) gained.
Results
Q1 was sent to 160 specialists involved in diagnosis and
treatment process in the oncology field: 17 molecular biologists
(10.7%), 21 surgeons (13.1%), 85 oncologists (53.1%), 37
pathologists (23.1%). These 160 specialists define a representative
sample of the different Italian regions. The 108 respondents
(67.5% of those initially selected) were from northern (43%),
central (28%) and southern (29%) Italy. Q2 was sent to the 108
responders to Q1, and 96 (88.8% of them) returned an answer.
The percentage of respondents choosing each reply is presented
in tables 1 and 2. By analyzing and evaluating the replies to both
questionnaires, the board identified the following statements about
different issues on KRAS testing that attained expert agreement of
67% or more:
Management of Patients with Metastatic Colorectal
Cancer
1. The determination of KRAS status is a key element in deciding
the therapeutic strategy of patients with metastatic CRC (Q1–
19)
2. In clinical practice, the molecular parameters used routinely for
the selection of first choice treatment in patients with metastatic
CRC are primarily KRAS mutations in exons 12 and 13 (Q1–
21)
3. KRAS evaluation allows for an efficient use of resources,
favoring the choice of the most appropriate and targeted
treatment (Q1–13; Q2–8)
4. Both primary tumor and metastases may be appropriate for
KRAS testing (Q1–22)
5. In a patient with metastatic CRC who must undergo a first-line
chemotherapy, a time interval of more than 15 days for the
result of KRAS testing limits the therapeutic choices (Q1–7;
Q2–4)
6. The maximum acceptable time for KRAS test result should not
exceed 10 days (Q2–5)
7. In patients with CRC and potentially resectable liver
metastases susceptible of conversion therapy, waiting time for
KRAS test result must be adequate in order to ensure the
eventual use of a monoclonal anti-EGFR antibody in
combination with chemotherapy (Q1–12)
8. If waiting time for KRAS test result is too long, a therapeutic
strategy alternative to the personalized therapy is not equally
effective (Q1–11; Q2–7; Q2–7a)
Definition of Colorectal Cancer Operated Patients at High
Risk of Relapse
1. In radically resected N0 patients, the most significant
prognostic factors are pT4, tumor grade, intestinal occlusion/
perforation at presentation (Q1–16)
2. In radically resected N+ patients, the most significant
prognostic factors are pN2 and pT4 (Q1–17)
3. Patients with surgically removed limited peritoneal carcinoma-
tosis and/or positive peritoneal washing and/or removed
ovarian metastases always require KRAS determination (Q1–
18)
Anticipation of KRAS Testing at the Diagnosis of Primary
Tumor
1. In patients at high risk of relapse anticipating KRAS testing
before the onset of metastatic disease may allow the timely use
of the most appropriate therapy when the patients metastasizes
(Q1–14; Q2–6b; Q2–8)
2. In patients at high risk of relapse, the best time for KRAS
testing is after radical resection of CRC in order to have the
information when it should be necessary (Q1–9)
3. Anticipating KRAS testing before the onset of metastatic
disease in patients at high risk does not affect the sustainability
of cetuximab in first-line mCRC regardless of the level of risk of
developing metastases (Q1–14; Q2–8)
Cost effectiveness results of early KRAS testing in high risk
patients that would have no access to well-timed KRAS testing if
they develop metastatic disease are summarized in Table 3.
In this table the treatment with cetuximab+FOLFOX-4 is
compared to FOLFOX-4 and bevacizumab+FOLFOX-4, while
cetuximab+FOLFIRI is compared to FOLFIRI. Anticipating the
KRAS testing has as consequence an increase of the costs for the
metastatic population represented by the cost of KRAS tests of
those patients that will not develop metastases and for which the
test would not be necessary. In order to simulate the incremental
cost effectiveness that would be generated by early KRAS testing
in high risk patients and to test the robustness of results, we
conducted several analyses under different assumptions, by setting
the level of risk of developing metastatic disease at the level of 1
patients out of 2 (i.e. 50% chance), 1/3, 1/4, 1/5 and 1/10, i.e.
including very low risk. The range of ICER generated is between
9,948.51 Euro/QALY (ICER1) and 10,903.73 Euro/QALY
(ICER5), far within the threshold of 60,000 Euro/QALY gained
accepted by regulatory institutions in Italy.
Discussion
The Delphi method used in the present analysis has advantages
and drawbacks. The methodology can overcome many of the
limitations intrinsic to traditional group decision-making processes,
it keeps attention directly on the issue, and it is flexible and
inexpensive compared to focus group. Depending on the nature of
the problem, the method can be adjusted for improved overall
efficacy. Since the use of strict statistical methods for setting
guidelines is rather problematic, due to the quantitative nature of
the expected results, the use of modified classification procedures
makes easier monitoring and expression of the process by which a
consensus is developed. On the other hand, there are some
disadvantages: information comes from a selected group of people
and may be not representative; it tends to eliminate extreme
positions and to force a middle-of-the-road consensus; it is more
time-consuming than group process methods; it requires skills in
written communication; finally, it requires adequate time and
participant commitment.
At the end, the consensus process has become part of the
technology for solving problems in health service and medicine by
putting the knowledge and experience of practitioners and other
experts in touch with scientific literature [30].
In advanced CRC the treatment strategy based on KRAS status
is related to clinical outcome of patients [3,5]. Determining the
tumor K-RAS status is now part of clinical practice in most
KRAS Early Test in Metastatic Colorectal Patients
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countries; for example, in France the prescription rate in first line
therapy is estimated around 81% [10]. In the present study most of
experts come from centers certified by the national quality
program for KRAS testing or participating to the KRAS aKtive
program, so their opinion reflects both the clinical attitude and the
real situation in treatment of CRC cancer in Italy. They strongly
agree on the relevance of KRAS mutational status in the decision
process in metastatic CRC because it allows both the choice of the
most appropriate treatment and the proper use of resources.
Although other mutations in KRAS, BRAF and PIK3CA genes
have been evaluated in relation to resistance to anti-EGFR
antibodies, only the most frequent seven KRAS mutations of
exons 12 and 13 (Gly12Ala, Gly12Asp, Gly12Arg, Gly12Cys,-
Gly12Ser, Gly12Val, Gly13Asp) have been investigated in phase
III clinical trials and have a proven relation to clinical efficacy of
anti-EGFR antibodies [5,31]. Accordingly, most panelists in our
analysis believe that only these mutations should be considered in
the practice and that accuracy in the determination of the test is
not affected by the source of the sample, either the primary tumor
or metastases.
Despite about 40% of experts think that time required to obtain
the result of KRAS test do not affect treatment choice in first-line
treatment of metastatic CRC, based on their experience, most of
them doubt that presently an alternative therapeutic choice might
have the same level of effectiveness when the possibility of
personalizing treatment were deemed. In addition, large percent-
age of panelists agree that in first-line chemotherapy a time
interval longer than 15 days for obtaining the result actually could
limit the therapeutic choices. In support of this view, an interval of
10 days has been considered an optimal time, suggesting that
waiting longer is not rare. As a matter of fact, in the previously
mentioned KRAS aKtive system it has been shown that delay in
obtaining KRAS testing is more than 15 days in most of Italian
regions [9].
The clinical situation, however, seems to influence the relevance
of shortening the time needed for having test results. In fact, a very
large percentage of panelists agree that, in conversion therapy of
liver metastases, waiting time for KRAS test must allow the use of
a monoclonal anti-EGFR antibody in combination with chemo-
therapy. This partial divergence may be the consequence of two
different aspects: on the one hand, response and tumor shrinkage
is largely perceived as important in conversion therapy, as it results
in several clinical studies. On the other hand, Italian regulatory
rules allow to use cetuximab later whether it was not used in first-
line. Therefore, some oncologists might conceive that, when
response does not seem to have a crucial role, the activity of
cetuximab might be recovered in a subsequent line of treatment.
However, this thinking does not consider that a number of KRAS
positive patients not responding to an alternative treatment might
be definitively excluded from EGFR targeting therapy due to
progressive disease, deterioration of performance status and
eventually death.
In the metastatic CRC, only when the mutational status of
KRAS is known, a proper therapeutic decision may be reached.
Panelists agree that in patients with metachronous metastases this
may be undoubtedly realized by anticipating KRAS test before the
onset of metastatic disease, meeting the need of improving decision
making in clinical practice, as it has been recently underlined [10].
In the opinion of most experts the right time for KRAS test is after
radical resection of CRC. This implies the need of identifying
which group of patients should be considered at high risk of
relapse. Panelists largely shared that conditions as surgically
removed limited peritoneal carcinomatosis and/or positive peri-
toneal washing and/or removed ovarian metastases have a very
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high risk of relapse and require an immediate assessment of KRAS
mutational status. In radically resected patients, according to
existing evidence, other unfavorable prognostic factors have been
recognized including: pT4, high tumor grade, intestinal occlusion-
perforation at presentation in N- patients, and pN2 followed by
pT4 in N+.
Contrary to what happens in other European countries, such as
Spain where a network do exist but all tests are referred to only
five laboratories [32], in Italy the system is more scattered in the
national territory [9] and the perception of relevance of the timing
of KRAS testing is diffuse. Therefore, the convergence of panelists
opinion toward the anticipation of KRAS testing in order to
ensure the timely use of the most appropriate and personalized
therapy in metastatic disease means that an anti-EGFR therapy
should be extensively considered in metastatic KRAS wt tumors.
As a consequence, the economic impact and sustainability of such
a strategy has been evaluated.
KRAS testing to limit use of EGFR inhibitors to patients with
KRAS wild-type tumors resulted in net savings of $7,500 to $1,200
and of J3,900 to J9,600 per patient in the United States and
Germany, respectively, and was shown cost-effective in patients
with KRAS wild-type liver limited disease [33,34]. It has been
estimated that KRAS testing to all metastatic CRCs may realize
annual savings ranging from $740 to $103 million in the United
States depending on parameters and alternative treatment
included in the analysis, that result in different outcomes in terms
of cost-effectiveness [35,36].
Our analysis was aimed to evaluate the different scenery of
KRAS early testing not in metastatic CRCs but in patients with
CRC at risk of relapse and/or metastases. Not all patients at high
risk will eventually develop metastases and will therefore be
eligible for treatment with cetuximab. The cost effectiveness of
early KRAS testing mimics the situation in which part of KRAS
test will be performed in vain (i.e. for those patients who will not
eventually develop metastases), and part will only be anticipated
(i.e. for those who will subsequently develop metastases). Compu-
tationally, this is equivalent to adding to the population of patients
eventually developing metastatic disease and being treated, the
cost of KRAS tests of the population of patients that will not
develop metastases and for which the test will not be necessary.
The results of this economic analysis on early KRAS testing in
CRC patients, including those at high as well those at very low
risk, show that the incremental cost-effectiveness ratio remains
within the range of 6,000 to 15,000 Euro per quality adjusted life
year (QALY) gained, regardless of the level of risk of developing
metastases and far within the threshold of 60,000 Euro/QALY
gained accepted by regulatory institutions in Italy (Table 3). In our
analysis, we hypothesized that the cost of promptly treating
patients developing metastases will include the cost of those KRAS
tests performed in patients that would not develop metastases. In
case of absence of timely knowledge on KRAS status, patients may
receive alternative treatments, which may be highly variable from
area to area, but it will essentially include a mix of FOLFOX/
FOLFIRI with or without bevacizumab. Therefore, in order to
allow the decision maker to judge based on the actual practice in
any relevant area, we assessed early KRAS testing against any
single alternative therapeutic strategy that may take place in
absence of adequate knowledge on KRAS status. In this way,
every decision maker can find information on each possible
relevant comparator assessed one by one against early KRAS test.
In other words, rather than assessing the ‘‘mix’’ of treatments that
patients may receive as a whole, we assessed each single part of the
mix, one by one against KRAS testing.
This study shows that anticipating KRAS testing in patients
with high risk of relapse is a strategy accepted and perceived as
useful by Italian specialists in the field of diagnosis and treatment
of CRC. A specifically modeled cost-effectiveness analysis suggests
that this clinical attitude is economically sustainable.
Taken together, the economic sustainability and the conver-
gence of panelists toward the anticipation of KRAS testing support
the inclusion of early KRAS testing in the joined recommenda-
tions of societies of Medical Oncology and Pathology in Italy. This
might represent the necessary condition for a larger national
program of guidelines in molecular diagnosis of cancer.
Glossary
Cost-Effectiveness Analysis (CEA). Analysis comparing the
costs and clinical outcomes of at least two therapeutic alternatives
(one of which may also be the non-treatment). Outcomes (benefits)
resulting from the alternatives are expressed in clinical units (e.g.
years of life gained, number of lives saved, reduction in the
incidence of a disease).
Cost-Utility Analysis (CUA). Analysis comparing the costs
and the consequences of at least two alternatives (one of which can
also be the non-treatment), capturing outcomes in terms of both
quantity and quality of life (utility) simultaneously. The outcomes
indicator generally used in a CUA is the QALY. The effects of
medical treatment are expressed in terms of quality-adjusted life
years gained (QALY).
Incremental Cost-Effectiveness Ratio (ICER). Ratio be-
tween the difference in costs and the difference of the outcomes
generated by the two alternatives (one of which may also be the
non-treatment). It is measured in terms of economic investment
required to achieve an incremental clinical benefit (Example:
Euro/QALY).
Quality Adjusted Life Years (QALY). Life year gained
multiplied by a factor between 1 and 0 (1 = full health, 0 = death),
which summarizes the quantity and quality of life impact in a
single index. The QALYs are used in the a-cost-utility analysis.
Willingness to pay. Amount of money that an individual/
society is willing to pay to obtain an outcome.
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